Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 25;10:10325. doi: 10.1038/s41598-020-67170-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Comparing the DNA hypomethylating activity of DHAs. (a) CEM leukemia cells were treated with different concentrations of decitabine (DAC), 5-azacytidine (5AC) and zebularine (Zeb) for 48 h followed by DNA extraction, DNA bisulfite treatment and DNA pyrosequencing of three CpG sites in the LINE-1 sequence (GenBank accession number X58075) as described under methods. (b) CEM leukemia cells were treated with different concentrations of decitabine (DAC) or RG-108 for 48 h followed by DNA extraction, DNA bisulfite treatment and DNA pyrosequencing of three CpG sites in the LINE-1 sequence as described under methods. (c) CEM leukemia cells were treated with different concentrations of decitabine (DAC), EGCG, 6-thioguanine (6-TG) or PEITC for 48 h followed by DNA extraction, DNA bisulfite treatment and DNA pyrosequencing of three CpG sites in the LINE-1 sequence as described under methods.(d) CEM leukemia cells were treated with different concentrations of decitabine (DAC), 5-azacytidine (5AC) and zebularine (Zeb) for 48 h followed by DNA extraction, DNA bisulfite treatment and DNA pyrosequencing of seven CpG sites in the CDKN2B (p15) sequence as described under methods. In all experiments, data represent the average of duplicates ± SD. *Indicates significant difference from the corresponding control CpG site at p < 0.05.